WO1998048775A1 - Serine protease and topical retinoid compositions - Google Patents
Serine protease and topical retinoid compositions Download PDFInfo
- Publication number
- WO1998048775A1 WO1998048775A1 PCT/US1998/002618 US9802618W WO9848775A1 WO 1998048775 A1 WO1998048775 A1 WO 1998048775A1 US 9802618 W US9802618 W US 9802618W WO 9848775 A1 WO9848775 A1 WO 9848775A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- topically active
- active agent
- pharmaceutical
- trypsin
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- This invention is related to methods for treating Acne Vulgaris and/or for producing anti-aging effects on the skin of a mammal, and compositions effective for the same. More specifically, the present invention is directed to the use of serine proteases, either alone or in combination with a retinoid compound in a pharmaceutical or cosmetic composition.
- Acne Vulgaris is a disorder of the pilosebaceous unit that affects nearly all adolescents to some degree, as well as many adults.
- the initial lesion of the disease is believed to be due to hypercornification and hyperkeratinization of the infundibulum, a process that helps to transform the sebaceous follicle into a comedone.
- This disorganization of the epithelium may give rise to inflammatory lesions, as the infundibulum ruptures and sebum is introduced into the dermis.
- traditional therapies are directed against the three major pathological processes which contribute to the development of Acne Vulgaris. Treatments such as topical retinoids work against the obstruction of the sebaceous follicle resulting from abnormal desquamation of the follicular epithelium.
- Hormonal agents target the androgen-stimulated increase in the production of sebum. Finally, antibiotics function to reduce and/or halt the proliferation of propionibacteria within the follicle which contribute to inflammation. Benzoyl peroxide, salicylic acid, and various cleansing agents are also employed for similar purposes. Topical retinoids are considered to be one of the most effective classes of comedolytic agents for the treatment of Acne Vulgaris, however their clinical efficacy is limited by their irritant effects.
- Topical retinoids have also been used to produce anti-aging effects on the surface of mammalian skin. While they are known in the art as one of the most effective topical treatments available, these compounds are limited by their irritant effects.
- a method for treating Acne Vulgaris and/or for producing anti-aging effects on the skin of a mammal comprising, consisting essentially of, or consisting of topically applying to the skin of a mammal an effective amount of a first topically active agent comprising a protease.
- a method for treating Acne Vulgaris and/or for producing anti-aging effects on the skin of a mammal comprising, consisting essentially of, or consisting of topically applying to the skin of a mammal an effective amount of a first topically active agent comprising a protease in combination with a second topically active agent comprising a retinoid.
- a pharmaceutical or cosmetic composition comprising, consisting essentially of, or consisting of: a) a first topically active agent comprising a protease; and b) a second topically active agent comprising a retinoid.
- compositions and methods of this invention provide a unique, convenient means for treating Acne Vulgaris and/or for producing anti-aging effects on the skin of a mammal.
- FIG. 1(a) is a representation which illustrates a cross-sectional view of the skin of a Rhino mouse one hour after treatment with fluorescently labeled trypsin.
- FIG. 1(b) is a representation which illustrates a cross- sectional view of the skin of a Rhino mouse four hours after treatment with fluorescently labeled trypsin.
- FIG (c) is a representation which illustrates a cross- sectional view of the skin of a Rhino mouse four hours after treatment with fluorescently labeled trypsin, following 5 days of daily treatment with 1% (w/v) trypsin.
- FIGS. 3(a) and 3(b) are representations which illustrate the histology of Rhino mouse skins processed with H&E staining, (a) untreated, and (b) treated daily with 0.1% (w/v) trypsin in GDL liposo es for five days.
- FIGS. 3(a) and 3(b) are color representations which illustrate the cross-sectional view of Rhino mouse skins which were processed for paraffin sections and stained for elastin.
- FIG. 3(a) is vehicle treated
- FIG. 3(b) is trypsin treated.
- FIGS. 3(c) and 3(d) are representations which illustrate the cross-sectional view of C57B1/6 mouse skins which were processed for paraffin sections and stained for elastin.
- FIG. 3(c) is vehicle treated
- FIG. 3(d) is trypsin treated.
- FIGS. 4 (a-c) are representations which illustrate the histology of Rhino mouse skins processed with H&E staining, (a) treated with 0.0005% (w/v) all-trans retinoic acid, (b) treated with 0.005% (w/v) trypsin, and (c) treated with both 0.0005% (w/v) all-trans retinoic acid and 0.005% (w/v) trypsin.
- FIGS. 5(a) and 5(b) are representations which illustrate the cross-sectional view of the TUNEL-stained skin tissue of a vehicle treated Rhino mouse.
- FIGS. 5(c) and 5(d) are representations which illustrate the cross-sectional view of the TUNEL-stained skin tissue of a Rhino mouse treated with trypsin.
- FIG. 6 is a representation which illustrates the profile of gene expression of trypsin treated Rhino mouse skins at various concentrations of trypsin as detected by Reverse Transcription-Polymerase Chain Reaction ("RT-PCR”) .
- RT-PCR Reverse Transcription-Polymerase Chain Reaction
- (w/v) shall mean grams of a given component per 100 ml of the total composition.
- Topically active agents suitable for use in the compositions of the present invention as the first topically active agent include proteases, which include, but are not limited to, serine proteases.
- the first topically active agent is selected from trypsin, carboxypeptidase-Y, protease IV, subtilysin, or mixtures thereof.
- the protease of choice is trypsin.
- the protease is present in an amount, based upon the total volume of the composition of the present invention, of from about 0% (w/v) to about 5% (w/v) , and more preferably from about 0.01% (w/v) to about 1% (w/v) .
- the first topically active agent of the present invention treats the hyperkeratinization associated with Acne Vulgaris and/or produces anti-aging effects on the skin.
- the first topically active agent can be used as the sole active ingredient in a composition for the treatment of Acne Vulgaris and/or to produce anti-aging effects on the skin, to more thoroughly treat Acne Vulgaris, the first topically active agent of the present invention can be combined with a second topically active agent.
- said second topically active agent treats both the hyperkeratinization and the obstruction of the sebaceous follicle associated with Acne Vulgaris, while also producing anti-aging effects on the skin which are comparable to those produced by the first topically active agent.
- the first feature of combining said first and second topically active agents is that the resulting treatment attacks at least two of the pathological processes associated with Acne Vulgaris, while not sacrificing the anti-aging benefits of the first topically active agent.
- Example 4 shows that combining said first topically active agent with said second topically active agent mitigates the irritant effect associated with said second topically active agent.
- the efficacy of treatment of Acne Vulgaris and/or signs of anti-aging effects on the skin are approximately the same with the treatments of the present invention as compared with treatments involving the second topically active agent alone, but the irritant effect normally associated with said second topically active agent is substantially reduced.
- Example 7 shows that combining said first topically active agent with said second topically active agent substantially reduces the time necessary for product efficacy as compared to the use of the second topically active agent alone.
- the efficacy of treatment remains approximately the same as compared with treatments utilizing the second topically active agent alone, but the length of time required to see results normally associated with said second topically active agent is substantially reduced by combining said second topically active agent with said first topically active agent.
- Topically active agents suitable for use in the compositions of the present invention as the second topically active agent include those compounds in the class of retinoids, which include, but are not limited to, retinoic acids, vitamin A alcohol, vitamin A aldehyde, retinyl acetate, retinyl palmitate, or other derivatives, analogs or mixtures thereof.
- the retinoid of choice is all-trans retinoic acid.
- the retinoid is present in an amount, based upon the total volume of the composition of the present invention, of from about 0.0001% (w/v) to about 0.5% (w/v), and more preferably from about 0.001% (w/v) to about 0.025% (w/v) .
- the pharmaceutical or cosmetic compositions of the present invention may preferably be further comprised of a pharmaceutically or cosmetically acceptable vehicle capable of functioning as a delivery system to enable the penetration of the topically active agent into the utriculus. While any commercially available vehicle for delivering the first topically active agent to the appropriate skin appendage, which in this case is the utriculus, is suitable for use as the pharmaceutically or cosmetically acceptable vehicle, liposomes are preferred.
- the liposomes are more preferably non-ionic and comprised of: (a) glycerol dilaurate or glycerol distearate; (b) compounds having the steroid backbone found in cholesterol; and (c) fatty acid ethers having from about 12 to about 18 carbon atoms, wherein the constituent compounds of the liposomes are in a ratio of about 53:10:22 to about 63:20:32, and preferably from about 55:12:24 to about 61:18:30, respectively.
- Liposomes comprised of glycerol dilaurate / cholesterol / polyoxyethylene-10-stearyl ether ("GDL”) are most preferred.
- the liposomes are present in an amount, based upon the total volume of the composition, of from about 10 mg/mL to about 100 mg/mL, and more preferably from about 25 mg/mL to about 50 mg/mL. A ratio of about 58:15:27, respectively, is most preferred.
- Suitable liposomes may preferably be prepared in accordance with the protocol set forth in Example 2, though other methods commonly used in the art are also acceptable.
- the above described liposo al composition may be prepared by combining the desired components in a suitable container and mixing them under ambient conditions in any conventional high shear mixing means well known in the art for non-ionic liposomes preparations, such as those disclosed in Niemiec et al .
- the pharmaceutical or cosmetic composition of the present invention may be optionally combined with other ingredients such as moisturizers, cosmetic adjuvants, anti-oxidants, surfactants, foaming agents, conditioners, humectants, fragrances, viscosifiers, buffering agents, sunscreens, colorants, preservatives, and the like in an amount which will not destroy the liposomal structure, if present, in order to produce cosmetic or pharmaceutical products .
- other ingredients such as moisturizers, cosmetic adjuvants, anti-oxidants, surfactants, foaming agents, conditioners, humectants, fragrances, viscosifiers, buffering agents, sunscreens, colorants, preservatives, and the like in an amount which will not destroy the liposomal structure, if present, in order to produce cosmetic or pharmaceutical products .
- the first and second topically active agents of the present invention can be applied to the skin of a mammal either simultaneously or at different times.
- the first topically active agent can be administered in the morning and the second topically active agent can be administered in the afternoon.
- the second topically active agent can be administered in the morning and the first topically active agent can be administered in the afternoon.
- the first and second topically active agents can be administered together.
- the first and second topically active agents can be administered on alternate days.
- the treatments with the first and second topically active agents do not have to be given in a one-to-one dosage, so the first topically active agent can be administered for two days, while the second topically active agent is administered on the third day and so on.
- the previous five examples are provided only to illustrate some of the many different treatment regimens possible with the methods of the present invention. It should be understood that these examples are not limiting in any way to the treatment methods of the present invention, and that many other treatment regimens are possible.
- the pharmaceutical or cosmetic composition should be applied in an amount effective to treat Acne Vulgaris and/or produce anti-aging effects on the skin.
- amount effective shall mean an amount sufficient to cover the region of skin surface where treatment of Acne Vulgaris and/or production of anti- aging effects is desired.
- the composition is applied to the skin surface such that, based upon a square cm of skin surface, from about 2 ⁇ l/cm 2 to about 8 ⁇ l/cm 2 of topically active agent is present when treatment of Acne Vulgaris and/or production of anti- aging effects on the skin is desired.
- the invention illustratively disclosed herein suitably may be practiced in the absence of any component, ingredient, or step which is not specifically disclosed herein. Several examples are set forth below to further illustrate the nature of the invention and the manner of carrying it out. However, the invention should not be considered as being limited to the details thereof.
- Rhino Mouse System The Rhino mouse has been used as an experimental acne model to screen topically active comedolytic and antikeratinizing agents as described in Sundberg, J.P., "The Hairless and Rhino Mutations, Chromosome 14," Handbook of Mouse Mutations With Skin and Hair
- a recessive mutation on chromosome 14 results in a mouse with wrinkled skin devoid of body hair by age 25 days.
- the end of the first hair cycle the follicular papillae fail to follow the regressing hair follicles and become isolated in the dermis.
- the papillae do not reassociate with the follicular epithelium to initiate a new hair follicle cycle.
- the upper remnants of the hair follicle are filled with sloughed, cornified cells and form utriculi with a small sebaceous gland at their base, resembling an open comedone.
- the rhino skin becomes progressively loose, forming folds and ridges, due to the expansion of the surface, secondary to abortive hair follicles filling with cornified debris.
- the utriculi progressively enlarge, forming pilary cists (pseudocomedones) , which are dilated follicular infundibula filled with cornified debris .
- RHJ/LE Hairless (“Rhino") male mice 5-7 weeks of age, were obtained from Jackson Laboratories (Bar Harbor, Maine) , and treated as described in Mezick et al .
- EXAMPLE 2 Preparation of Topically Active Compositions A sufficient amount of lyophilyzed trypsin, available from Sigma-Aldrich Corporation (St. Louis, Missouri) , was mixed into a buffered aqueous solution of 0.05 M N-2-hydroxyethylpiperazine-N' -2-ethane sulfonic acid available from Life Technologies, Inc. (Gaithersburg, Maryland) under the tradename "Hepes" such that the pH of the resulting solution was about 7.4 and the concentration of trypsin in the solution was about 2% (w/v) .
- glycerol dilaurate was available from International Specialty Products Van Dyke (Belleville, New Jersey) under the tradename "Emulsynt GDL.”
- the cholesterol was available from Croda, Inc. (Parsippany, New Jersey) under the tradename "Cholesterol VSP/NF.”
- the polyoxyethylene-10-stearyl ether was available from ICI Surfactants Americas
- Retinoic acid compositions contained an ethanol/propylene glycol vehicle which comprised 70% (w/v) ethanol (ethyl alcohol, 200 proof) which was obtained from Quantum Chemicals Corporation (Tuscola, Illinois) and 30% (w/v) propylene glycol which was obtained from Fisher Scientific (Pittsburgh,
- the all-trans retinoic acid used in the retinoic acid compositions was obtained from BASF Aktiengesellschaft (Ludwigshafen, Germany) .
- the volume to volume ratio of all-trans retinoic acid to ethanol/propylene glycol vehicle, respectively, was altered to produce various concentrations of retinoic acid compositions.
- EXAMPLE 3 Delivery of Trypsin into Hair Follicles About 100 ⁇ L of the topically active trypsin composition of Example 2 was applied to the dorsal side of each Rhino mouse of Example 1. The trypsin used in this composition was fluorescently-labeled with a protein fluorescent labeling kit available from Molecular Probes, Inc. in accordance with its accompanying protocol (1996).
- Rhino mice of Example 1 were topically treated with the trypsin compositions (0.001% (w/v) - 1% (w/v)) of Example 2 once daily for five days. Animals were sacrificed at day 8 and image analysis was used to quantify the reduction in utriculi size. For image analysis, whole mount epidermis was processed and microscopic measurements were taken according to the methods described in Mezick as well as Bernerd et aJ.,
- Rhino mice using 5 random fields, two measurements per field, per animal. Percent reduction in utriculi diameter was calculated in accordance with the methods described in Finney, D.J., "Parallel Line Assays, Statistical Method in Biological Assay, " Charles Griffen & Company Ltd. 69-104 (1978) which is incorporated herein by reference in its entirety.
- trypsin induced a dose dependent reduction in utriculus size that reached a plateau at ⁇ 0.1% (w/v) trypsin.
- a further increase in trypsin concentration did not result in more than 55% reduction of utriculus size relative to liposomal control.
- a small reduction in utriculus diameter was observed in the liposome vehicle alone.
- a single trypsin (1% (w/v)) treatment had no effect on utriculus size reduction when analyzed seven days later (not shown) .
- Liposome Vehicle 13.2 ⁇ 1.82* 19.8 ⁇ 1.14 * Percent of utriculus size reduction of the liposome vehicle treatment was calculated relative to the untreated control
- TEWL transepidermal water loss
- TEWL increased in a dose dependent manner, with a plateau reached at ⁇ 0.05% (w/v) trypsin. This is approximately the same concentration for the maximal reduction in utriculi diameter. There was no correlation between TEWL increase and visual irritation. The minor scaling and erythema observed throughout these experiments were not dose dependent and remained low even at 1% (w/v) trypsin. Furthermore, the TEWL for trypsin treated mice was lower than that for retinoid treatment given alone.
- FIG.2 (b) shows no inflammatory cells, which would normally be present in an irritation situation.
- This example shows that trypsin causes a dose dependent reduction in the size of utriculi. A reduction in the size of the utriculi is associated with potential clinical efficacy of compositions for treating Acne Vulgaris. Therefore, this example further shows that trypsin is effective in the treatment of Acne Vulgaris. This example further shows that topical trypsin treatments do not induce skin irritation.
- EXAMPLE 5 Trypsin Treatment Results in Increased Skin Elasticity Rhino mice of Example 1 which were treated with the trypsin composition of Example 2 showed a noticeable effect in skin elasticity. To quantitate this effect, a cutometer analysis was performed. We used a cutometer available from Acaderm (Menlo Park, California) , and employed the methods described in Couturaud et al . ,
- elastin fibers (stained purple) were increased in thickness and density around the utriculi and the sebaceous glands of the trypsin treated Rhino mice when compared to the untreated mice of FIG. 3(a) .
- FIGS. 3(c) and (d) show the results of elastin staining.
- Table 3 below shows the increase in skin mechanical parameters following the trypsin treatment.
- This example shows that topical treatment with trypsin increases the elasticity of C57B1/6 and Rhino mouse skins. Skin elasticity is a property associated with anti-aging. Therefore, this example further shows that trypsin imparts anti-aging effects to the surface of the skin.
- Liposome Vehicle 94698.9 ⁇ 4997.1 4.45 ( vs . untreated) Trypsin 0.5% (w/v) 95043.0 ⁇ 4269.1 -0.36 ( vs . liposome vehicle)
- this example further suggests that trypsin functions with a mechanism different from that of retinoid compounds.
- a first set of Rhino mice of Example 1 were treated with suboptimal doses of the trypsin composition of Example 2.
- “suboptimal” is defined as levels of trypsin concentration below the optimum for utriculi size reduction as demonstrated in Example 4.
- a second set of Rhino mice of Example 1 were treated with suboptimal concentrations of the all-trans retinoic acid composition of Example 2.
- a third set of Rhino mice of Example 1 were treated with both suboptimal doses of the trypsin composition of Example 2 and the all-trans retinoic acid composition of Example 2. In this third set of Rhino mice, the trypsin and all-trans retinoic acid treatments were each administered daily, but at different times (i.e.
- Rhino mice treated with both the trypsin and all-trans retinoic acid compositions showed much improved desquamation when compared to the trypsin and all-trans retinoic acid treatments given alone (FIGS. 4 (a&b) ) , though the treatments given alone showed marked inprovement over the untreated skin (FIG. 2 (a) ) .
- the histological analysis revealed far fewer open utriculi in the surface of treated skins than either treatment given alone.
- Rhino mice of Example 1 were treated daily with a 0.1% (w/v) trypsin composition of Example 2 for five days and sacrificed at day eight.
- TUNEL TdT-mediated dUTP-biotin nick end labeling
- FIGS. 5(a-d) show a histological analysis wherein the stain has a peroxidase end point (brown) and a methyl green counter-stain. The resulting representations of this are provided in FIGS. 5(a&b) which are vehicle treated and FIGS. 5(c&d) which are trypsin treated.
- the TUNEL-stained samples defined apoptotic cells by both morphology (condensed or fragmented nuclei and cytoplasm or apoptotic bodies) and by the color of its stain (fragmented DNA within the condensed nuclei were stained brown).
- TUNEL staining revealed an unusually high level of apoptotic bodies in the follicular epithelium. Trypsin treatment resulted in the elimination of all the apoptotic bodies within the follicular epithelium and the restoration of programmed cell death ("PCD") at the granular layer (FIGS. 5(c&d)) as epidermal differentiation was restored.
- PCD programmed cell death
- This example suggests that trypsin could restore the balance between cell death and proliferation within the follicular epithelium and within the epidermis.
- One of the contributing pathological processes of Acne Vulgaris is hyperkeratinization, which may result from a shift in this balance. Therefore, this example further shows that the ability of trypsin to restore the proper balance in epithelial cell death and proliferation may be a factor in its ability to treat Acne Vulgaris.
- EXAMPLE 9 Trypsin Induces Changes in Gene Expression Rhino mice of Example 1 were treated daily with trypsin compositions (0% (w/v), 0.0001% (w/v), 0.001% (w/v), and 0.01% (w/v)), as prepared in Example 2, for five days and sacrificed at day eight. The skins of vehicle treated mice and trypsin-treated mice were obtained as described in Example 3, then their total RNAs were extracted using "RNA Stat-60" reagent available from Tel-Test "B,” Inc. as described in Chomczymski, "Single Step Method of RNA Isolation By Acid Guanidinium Thiocyanate-phenol-chloroform extraction," 162 Anal. Biochem.
- RT products were then amplified via a polymerase chain reaction ("PCR") using about a 0.5 unit (per 100 ⁇ l reaction) of a thermostable DNA polymerase which is commercially available from Perkin-Elmer-Cetus Corporation under the tradename "Taq polymerase," and about 0.1 ⁇ mol/reaction of mouse glyceraldehyde-3- phosphate-dehydrogenase (G3PDH) primers available from Clontech Laboratories, Inc. (“Clontech”) , or primers as set forth in Table 4 (using the conditions in Table 4 or in accordance with the procedures set forth in the protocol accompanying the primers from Clontech) .
- PCR polymerase chain reaction
- Table 5 illustrates some of the DNA primers used, the amount of MgCl 2 required for the PCR reaction, and the length of the PCR cycle. Involucrin primers were as described in Marthinuss, et al . , "Apoptosis in Pam212, an Epidermal Keratinocyte Cell Line: A Possible Role for bcl-2 in Epidermal Differentiation", 6 Cell Growth Diff.
- RNA sample from the skin of a cell was analyzed on 2% agarose/ethidium bromide gels according to methods well- known in the art in order to compare the level of expression of certain genes in skins of trypsin-treated and untreated mice.
- T ⁇ n RNA sample from the skin of a cell was analyzed on 2% agarose/ethidium bromide gels according to methods well- known in the art in order to compare the level of expression of certain genes in skins of trypsin-treated and untreated mice.
- Rhino mouse that was not reverse-transcribed was used as a negative control for each PCR amplification.
- An RNA sample from the skin of a six month old Rhino mouse was used as a positive control when positive controls were not commercially available.
- the results of the gel analysis showed that the migration of the RT-PCR products on the gels was always identical to that of the positive controls, and to that of the reported amplimer sizes .
- the relative quality of each respective RT-PCR reaction product was then compared by analyzing the mRNA level of G3PDH, a "housekeeping" gene, in each respective product. As illustrated in FIG. 6, G3PDH gene expression was found to be similar in all samples examined, which thereby enabled the analysis of the relative levels of gene expression for the desired genes . 775
- Transglutaminase an enzyme involved in the cross linking and formation of apoptotic bodies, displayed high mRNA levels in control animals, and was reduced to below detection level with increasing concentrations of trypsin. This shows that trypsin restored utriculi homeostasis and eliminated abnormally high levels of apoptosis in the follicular epithelium.
- Elastin mRNA increased following treatment with increasing concentrations of trypsin. Therefore, new elastin is expressed following trypsin treatment which results in increased skin elasticity, as described in Example 5.
- involucrin a marker of epidermal differentiation
- Trypsin-induced changes in mRNA levels were clearly evidenced, indicating a regulatory role for trypsin in PCD, apoptosis, elastin expression, and epidermal differentiation.
- EXAMPLE 10 Use of Compositions Containing' Trypsin and All-Trans Retinoic Acid Glycerol dilaurate/cholesterol/polyoxyethylene-10- stearyl ether liposomes are prepared in accordance with the procedures set forth in Niemiec, wherein the constituent compounds of the liposomes are in a ratio of about 58:15:27, respectively. Prior to mixing the lipid and water phases to form the liposomes of Niemiec, 0.1% (w/v) ascorbic acid is added to the water phase, and the ingredients listed in Table 5 are added to the lipid phase of the composition. The final pH of this composition is adjusted to a range of 4 to 1 , and prefereably from 4.5 to 5.5 with a suitable buffer.
- a second composition which comprises l.Og trypsin disolved in a 0.05M Hepes buffer, at pH 7.4 (q.s. to 100ml), is added to the liposome composition in a ratio of about 1 part of the second composition for every 8 parts of the liposome composition.
- This final composition is suitable for immediate topical application.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19882420T DE19882420T1 (en) | 1997-02-12 | 1998-02-06 | Serine protease and local retinoid compositions |
AU65345/98A AU749215B2 (en) | 1997-02-12 | 1998-02-06 | Serine protease and topical retinoid compositions |
BR9812996-1A BR9812996A (en) | 1997-02-12 | 1998-02-06 | Serine protease and topical retinoid compositions |
CA002280747A CA2280747A1 (en) | 1997-02-12 | 1998-02-06 | Serine protease and topical retinoid compositions |
MXPA99007442A MXPA99007442A (en) | 1997-02-12 | 1998-02-06 | Serine protease and topical retinoid compositions. |
IL13132298A IL131322A0 (en) | 1997-02-12 | 1998-02-06 | Serine protease and topical retinoid compositions |
JP54694698A JP2002515903A (en) | 1997-02-12 | 1998-02-06 | Composition of serine protease and topical retinoid |
FI992177A FI19992177A (en) | 1997-02-12 | 1999-10-11 | Serine protease and locally useful retinoid compositions |
DK199901456A DK199901456A (en) | 1997-02-12 | 1999-10-12 | Serine protease and topical retonoid preparations |
SE9904059A SE9904059D0 (en) | 1997-02-12 | 1999-11-10 | Serine protease and topical retinoid compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3760597P | 1997-02-12 | 1997-02-12 | |
US60/037,605 | 1997-02-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998048775A1 true WO1998048775A1 (en) | 1998-11-05 |
WO1998048775A9 WO1998048775A9 (en) | 1999-03-04 |
Family
ID=21895246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/002618 WO1998048775A1 (en) | 1997-02-12 | 1998-02-06 | Serine protease and topical retinoid compositions |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP2002515903A (en) |
CO (1) | CO4950526A1 (en) |
DK (1) | DK199901456A (en) |
FI (1) | FI19992177A (en) |
TW (1) | TW590771B (en) |
WO (1) | WO1998048775A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1060732A2 (en) * | 1999-05-27 | 2000-12-20 | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. | Novel topical formulations comprising vesicle delivery systems |
WO2000078332A2 (en) * | 1999-06-18 | 2000-12-28 | Jon Bragi Bjarnason | Fish serine proteinases and their pharmaceutical and cosmetic use |
FR2817475A1 (en) * | 2000-12-04 | 2002-06-07 | Rocher Yves Biolog Vegetale | Use of a composition, comprises proteases and a retinol source to combat skin aging |
US10828243B2 (en) | 2015-03-05 | 2020-11-10 | Avon Products, Inc. | Methods for treating skin |
WO2023099793A1 (en) * | 2021-12-03 | 2023-06-08 | Dsm Ip Assets B.V. | Novel compositions comprising retinoids |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004508392A (en) * | 2000-09-13 | 2004-03-18 | ザ、プロクター、エンド、ギャンブル、カンパニー | Makeup method |
AU2000274801A1 (en) * | 2000-09-13 | 2002-03-26 | The Procter And Gamble Company | Cosmetic method for treatment of skin and/or hair |
AU2000273752A1 (en) * | 2000-09-13 | 2002-03-26 | The Procter And Gamble Company | Cosmetic method |
BR112017019054B1 (en) * | 2015-03-05 | 2021-05-11 | Avon Products, Inc | cosmetic, non-therapeutic method to decrease dermatological signs of aging in human skin and skin care products |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04364119A (en) * | 1991-06-11 | 1992-12-16 | Tsumura & Co | Bathing agent composition |
DE4305460A1 (en) * | 1993-02-23 | 1994-08-25 | Albert Dr Scheller | Pharmaceutical or cosmetic preparation comprising enzymes, process for their preparation and their use |
WO1995007688A1 (en) * | 1993-09-15 | 1995-03-23 | Unilever Plc | Skin care method and composition |
EP0759293A1 (en) * | 1995-07-25 | 1997-02-26 | L'oreal | Stable composition containing an enzyme |
WO1997025059A1 (en) * | 1996-01-09 | 1997-07-17 | Beiersdorf Ag | Using serine-proteases for acne and inflamed comedones |
WO1997047283A1 (en) * | 1996-06-13 | 1997-12-18 | Active Organics, Inc. | Combination of acid protease enzymes and acidic buffers and uses thereof |
-
1998
- 1998-02-06 JP JP54694698A patent/JP2002515903A/en active Pending
- 1998-02-06 WO PCT/US1998/002618 patent/WO1998048775A1/en not_active Application Discontinuation
- 1998-02-12 CO CO98007364A patent/CO4950526A1/en unknown
- 1998-04-08 TW TW87101981A patent/TW590771B/en not_active IP Right Cessation
-
1999
- 1999-10-11 FI FI992177A patent/FI19992177A/en unknown
- 1999-10-12 DK DK199901456A patent/DK199901456A/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04364119A (en) * | 1991-06-11 | 1992-12-16 | Tsumura & Co | Bathing agent composition |
DE4305460A1 (en) * | 1993-02-23 | 1994-08-25 | Albert Dr Scheller | Pharmaceutical or cosmetic preparation comprising enzymes, process for their preparation and their use |
WO1995007688A1 (en) * | 1993-09-15 | 1995-03-23 | Unilever Plc | Skin care method and composition |
EP0759293A1 (en) * | 1995-07-25 | 1997-02-26 | L'oreal | Stable composition containing an enzyme |
WO1997025059A1 (en) * | 1996-01-09 | 1997-07-17 | Beiersdorf Ag | Using serine-proteases for acne and inflamed comedones |
WO1997047283A1 (en) * | 1996-06-13 | 1997-12-18 | Active Organics, Inc. | Combination of acid protease enzymes and acidic buffers and uses thereof |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Week 9206, Derwent World Patents Index; AN 92-043740, XP002073069 * |
STN, File Supplier, Karlsruhe, DE, File * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1060732A2 (en) * | 1999-05-27 | 2000-12-20 | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. | Novel topical formulations comprising vesicle delivery systems |
EP1060732A3 (en) * | 1999-05-27 | 2001-12-12 | JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. | Novel topical formulations comprising vesicle delivery systems |
WO2000078332A2 (en) * | 1999-06-18 | 2000-12-28 | Jon Bragi Bjarnason | Fish serine proteinases and their pharmaceutical and cosmetic use |
WO2000078332A3 (en) * | 1999-06-18 | 2001-07-05 | Jon Bragi Bjarnason | Fish serine proteinases and their pharmaceutical and cosmetic use |
FR2817475A1 (en) * | 2000-12-04 | 2002-06-07 | Rocher Yves Biolog Vegetale | Use of a composition, comprises proteases and a retinol source to combat skin aging |
DE10065704B4 (en) * | 2000-12-04 | 2007-05-03 | Laboratoires de Biologie Végétale Yves Rocher | Use of a combination of proteases and a retinol source to combat skin aging |
US10828243B2 (en) | 2015-03-05 | 2020-11-10 | Avon Products, Inc. | Methods for treating skin |
WO2023099793A1 (en) * | 2021-12-03 | 2023-06-08 | Dsm Ip Assets B.V. | Novel compositions comprising retinoids |
Also Published As
Publication number | Publication date |
---|---|
DK199901456A (en) | 1999-10-12 |
JP2002515903A (en) | 2002-05-28 |
CO4950526A1 (en) | 2000-09-01 |
FI19992177A (en) | 1999-10-11 |
TW590771B (en) | 2004-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5614215A (en) | Cosmetic composition for the simultaneous treatment of the surface and deep layers of the skin, its use | |
Tabbakhian et al. | Enhancement of follicular delivery of finasteride by liposomes and niosomes: 1. In vitro permeation and in vivo deposition studies using hamster flank and ear models | |
CA2552607C (en) | Cosmetic composition and method for retarding hair growth | |
Lauer et al. | Targeted delivery to the pilosebaceous unit via liposomes | |
AU722917B2 (en) | Methods for altering hair growth and hair pigmentation by apoptosis in the follicular papillae and compositions therefor | |
Weiner et al. | Liposomes: a novel topical delivery system for pharmaceutical and cosmetic applications | |
EP2244690B1 (en) | Topical compositions for treating inflammatory disorders, diseases and conditions | |
JPH01199910A (en) | Anti-acne composition | |
HUT71722A (en) | Anti-acne composition for the simultaneous treatment of the surface layers and deep layers of the skin, and use thereof | |
JPH07258076A (en) | Composition for skin disease of which effective component is amphoteric lactate amino acid | |
HUT71727A (en) | Composition for combating ageing of the skin, acting simultaneously on the surface layers and deep layers of the skin, and use thereof | |
JP2000512298A (en) | Combination of acid protease enzyme and acid buffer and its use | |
JP2000510456A (en) | Oxodiic acids and related compounds for the treatment of skin conditions | |
WO1998048775A1 (en) | Serine protease and topical retinoid compositions | |
WO1998048775A9 (en) | Serine protease and topical retinoid compositions | |
NZ504458A (en) | Use of a mixture of a diol and an alpha-hydroxy acid in a semi-occluding vehicle for the treatment of hyperkeratotic skin diseases | |
Moghimi et al. | Current progress and future prospects of liposomes in dermal drug delivery | |
US20020172672A1 (en) | Serine protease and topical retinoid compositions useful for treatment of acne vulgaris and production of anti-aging effects | |
US6407056B1 (en) | Methods for altering hair growth and hair pigmentation by apoptosis in the follicular papillae and compositions therefor | |
Seiberg et al. | The Effects of Tryspin on Apoptosis, Utriculi Size, and Skin Elasticity in the Rhino Mouse | |
JP2002128702A (en) | Method for enhancing efficacy of locally active ingredient by mono-acyl-(lyso)-glycerophospholipid and its use | |
EP1080719A2 (en) | Methods for potentiation of efficacy of topical actives by mono-acyl-(lyso)-glycerophosholipids | |
JPH115742A (en) | External preparation containing cholesterol sulfate | |
JP3117823B2 (en) | Collagen metabolic activator | |
JP2574732B2 (en) | Collagen metabolic activator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 131322 Country of ref document: IL Ref document number: 98802506.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1-30, DESCRIPTION, REPLACED BY NEW PAGES 1-21; PAGES 31-38, CLAIMS, REPLACED BY NEW PAGES 22-27; PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 65345/98 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2280747 Country of ref document: CA Ref document number: 2280747 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/007442 Country of ref document: MX Ref document number: 1019997007261 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 19992177 Country of ref document: FI |
|
ENP | Entry into the national phase |
Ref document number: 1998 9048 Country of ref document: AT Date of ref document: 19981105 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 19989048 Country of ref document: AT |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997007261 Country of ref document: KR |
|
RET | De translation (de og part 6b) |
Ref document number: 19882420 Country of ref document: DE Date of ref document: 20010215 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 19882420 Country of ref document: DE |
|
WWG | Wipo information: grant in national office |
Ref document number: 65345/98 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: PT Ref legal event code: FC3A |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997007261 Country of ref document: KR |